News

Gujarat Themis Biosyn Limited has allotted Non-Convertible Debentures (NCDs) aggregating Rs 585 crore on a private placement basis, according to a filing with the National Stock Exchange of India and the BSE Limited on September 16, 2026. The company intends to utilize the proceeds to invest in its wholly-owned subsidiary in Japan to finance the acquisition of MicroBiopharm Japan Co., Ltd, and for general corporate purposes. The NCDs consist of 58,500 debentures with a nominal value of Rs 100,000 each, split into two series: Series 1 aggregating Rs 2,950,000,000 and Series 2 aggregating Rs 2,900,000,000.

Gujarat Themis Biosyn Limited will hold a board meeting on September 1, 2026, to approve raising funds through the issue of equity shares and/or convertible warrants via a preferential issue on a private placement basis, according to a regulatory filing with the National Stock Exchange of India Limited and BSE Limited.

Gujarat Themis Biosyn Limited convened an Extraordinary General Meeting on Saturday, August 22, 2026, at its registered office in Vapi, Gujarat, where shareholders approved resolutions including the approval of material related party transactions with promoter/promoter group entities, an amendment to the company’s Articles of Association, and a private placement of NCDs and/or debt securities. The meeting, chaired by Dr. Dinesh S. Patel, was attended by 56 members in person or through representatives, and remote e-voting was conducted from August 19 to August 21, 2026, with Mr. Ketan R. Shirwadkar of M/s. KRS AND CO. serving as the scrutinizer.

Net profit of Gujarat Themis Biosyn rose 22.19% to Rs 11.07 crore in the quarter ended June 2026 as against Rs 9.06 crore during the previous quarter ended June 2025. Sales rose 22.08% to Rs 43.79 crore in the quarter ended June 2026 as against Rs 35.87 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales43.7935.87 22 OPM %47.5038.81 - PBDT19.1414.15 35 PBT15.1712.12 25 NP11.079.06 22 Powered by Capital Market - Live News

Gujarat Themis Biosyn announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 22 August 2026.